

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/563,731
	Filing Date	January 6, 2006
	First Named Inventor	Else Agger
	Art Unit	1645
<i>(Multiple sheets used when necessary)</i>	Examiner	Nina Archie
SHEET 1 OF 1	Attorney Docket No.	PLOUG8.001APC

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	Gregoriadis, G. (1995) Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13:527-537.	
	2	Hilgers et al. (1991) DDA as an immunological adjuvant. Res. Immunol. 143:494-503.	
	3	Koike et al. (1998) Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. 16(20):1982-1989	
	4	Moingeon et al. (2001) Towards the rational design of Th1 adjuvants. Vaccine. 19:4363-4372.	

8355497/bab/010810

Examiner Signature <u>/Nina Archie/</u>	Date Considered 1/14/2010
--	------------------------------

T¹ - Place a check mark in this area when an English language translation is attached.
 ALL PERTINENT INFORMATION IS CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./